Why Insurance Forces People to Opt for a Secondary Obesity Medication

Why Insurance Forces People to Opt for a Secondary Obesity Medication

CVS Caremark has chosen to favor Wegovy over Zepbound for weight management purposes. This decision is a recent instance of how insurance restrictions can interrupt patient treatments.

A significant number of individuals across the United States will soon be compelled by their insurance providers to switch from a well-known obesity drug to another option that is considered less effective in terms of weight reduction.

The Role of Pharmacy Benefit Managers

These changes are the latest outcomes of undisclosed contracts between pharmaceutical companies and intermediaries. These intermediaries, often referred to as pharmacy benefit managers, are engaged by employers to oversee prescription drug plans for their employees. While employers benefit from reduced medication costs, employees are often barred from accessing various treatment options. This form of coverage denial has notably increased over the last ten years.

A prominent figure in this space, CVS Health’s Caremark, has opted to remove Zepbound from their offering despite studies indicating superior weight loss results compared to Wegovy, which remains on their approved list.

Clinical Evidence and Research Findings

Evidence from research, originally highlighted in studies and later confirmed by The New England Journal of Medicine, reveals significant findings. The associated clinical trial, overseen by Eli Lilly, Zepbound’s producer, showed greater weight loss outcomes with Zepbound, supporting similar results from earlier studies.

Impact on Patients

Ellen Davis, a 63-year-old resident of Huntington, Massachusetts, exemplifies those affected by Caremark’s policy alteration. She expressed feeling destabilized by the decision. After a year of Zepbound, she successfully shed 85 pounds and noted improvements in her overall health. Davis retired following a 34-year tenure with Verizon, during which Caremark was responsible for her medication coverage.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts